{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:40:09Z","timestamp":1746290409061,"version":"3.40.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite of long-lasting tolvaptan treatment, individual renal outcomes are unclear in autosomal dominant polycystic kidney disease (ADPKD). This post-hoc analysis of the TEMPO 3:4 trial aimed to evaluate the predictability of estimated height-adjusted total kidney volume growth rate (eHTKV-\u03b1) on renal outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In TEMPO 3:4, 1445 patients with ADPKD were randomised to tolvaptan or placebo for 3 years. The present analysis included patients with total kidney volume (TKV) data available at baseline and month 12 (tolvaptan, <jats:italic>n<\/jats:italic>\u2009=\u2009812; placebo, <jats:italic>n<\/jats:italic>\u2009=\u2009453); tolvaptan-assigned patients were grouped into quartiles based on percent change in eHTKV-\u03b1 from baseline at 1 year. Clinical parameters were compared between quartiles, and regression analyses evaluated the predictive value of 1-year percent change in eHTKV-\u03b1 and other factors on annual changes in TKV and estimated GFR (eGFR) over 3 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Trend tests identified significant differences between quartiles for several baseline parameters. Multivariate regression models confirmed that 1-year percent change in eHTKV-\u03b1 was a significant predictor of annual changes in both TKV and eGFR over 3 years. Other significant predictors of annual changes in TKV and eGFR over 3 years were sex, age and body mass index, and first-year change in eGFR, race and baseline eGFR, respectively. Predicting factors using urine osmolality and plasma copeptin levels were not significant by backward stepwise selection analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>1-year percent change in eHTKV-\u03b1 is useful biomarker to identify treatment good responders and may be utilized for early estimate of trial outcomes of new drugs in ADPKD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10157-024-02589-1","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:12:25Z","timestamp":1735845145000},"page":"638-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6663-9910","authenticated-orcid":false,"given":"Eiji","family":"Higashihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67:792\u2013810.","journal-title":"Am J Kidney Dis"},{"key":"2589_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","volume":"7","author":"JJ Grantham","year":"2011","unstructured":"Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7:556\u201366.","journal-title":"Nat Rev Nephrol"},{"key":"2589_CR3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","volume":"57","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000;57:1460\u201371.","journal-title":"Kidney Int"},{"key":"2589_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1046\/j.1523-1755.1998.00990.x","volume":"54","author":"G Yasuda","year":"1998","unstructured":"Yasuda G, Jeffries WB. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int. 1998;54:80\u20136.","journal-title":"Kidney Int"},{"key":"2589_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136.","journal-title":"Nat Med"},{"key":"2589_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"2589_CR7","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"2589_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU M\u00fcller","year":"2022","unstructured":"M\u00fcller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022;37:825\u201339.","journal-title":"Nephrol Dial Transplant"},{"key":"2589_CR9","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29:2458\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"2589_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10157-015-1219-7","volume":"20","author":"S Horie","year":"2016","unstructured":"Horie S, Mochizuki T, Muto S, et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol. 2016;20:493\u2013509.","journal-title":"Clin Exp Nephrol"},{"key":"2589_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/IJNRD.S125942","volume":"11","author":"L Sans-Atxer","year":"2018","unstructured":"Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018;11:41\u201351.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2589_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","volume":"71","author":"GM Brosnahan","year":"2018","unstructured":"Brosnahan GM, Abebe KZ, Moore CG, et al. Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials. Am J Kidney Dis. 2018;71:666\u201376.","journal-title":"Am J Kidney Dis"},{"key":"2589_CR13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Gansevoort RT, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO3: 4 trial. J Am Soc Nephrol. 2017;28:1592\u2013602.","journal-title":"J Am Soc Nephrol"},{"key":"2589_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","volume":"96","author":"RT Gansevoort","year":"2019","unstructured":"Gansevoort RT, van Gastel MDA, Chapman AB, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019;96:159\u201369.","journal-title":"Kidney Int"},{"key":"2589_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/sj.ki.5002624","volume":"73","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ, Cook LT, Torres VE, et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 2008;73:108\u201316.","journal-title":"Kidney Int"},{"key":"2589_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"2589_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10157-018-1617-8","volume":"23","author":"E Higashihara","year":"2019","unstructured":"Higashihara E, Yamamoto K, Kaname S, et al. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2019;23:100\u201311.","journal-title":"Clin Exp Nephrol"},{"key":"2589_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.ekir.2020.06.011","volume":"5","author":"E Higashihara","year":"2020","unstructured":"Higashihara E, Fukuhara H, Ouyang J, et al. Estimation of changes in kidney volume growth rate in ADPKD. Kidney Int Rep. 2020;5:1459\u201371.","journal-title":"Kidney Int Rep"},{"key":"2589_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1159\/000511797","volume":"51","author":"E Higashihara","year":"2020","unstructured":"Higashihara E, Horie S, Muto S, et al. Imaging identification of rapidly progressing autosomal dominant polycystic kidney disease: simple eligibility criterion for tolvaptan. Am J Nephrol. 2020;51:881\u201390.","journal-title":"Am J Nephrol"},{"key":"2589_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ekir.2021.11.034","volume":"7","author":"E Higashihara","year":"2021","unstructured":"Higashihara E, Nutahara K, Itoh M, et al. Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD. Kidney Int Rep. 2021;7:270\u201381.","journal-title":"Kidney Int Rep"},{"key":"2589_CR21","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122\u201330.","journal-title":"N Engl J Med"},{"key":"2589_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2589_CR23","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/j.1523-1755.2005.00589.x","volume":"68","author":"KD Stringer","year":"2005","unstructured":"Stringer KD, Komers R, Osman SA, et al. Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int. 2005;68:1729\u201339.","journal-title":"Kidney Int"},{"key":"2589_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, You Z, Gitomer B, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29:571\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2589_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2215\/CJN.00840122","volume":"17","author":"RL McGill","year":"2022","unstructured":"McGill RL, Saunders MR, Hayward AL, et al. Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022;17:976\u201385.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2589_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/14656566.2024.2357188","volume":"25","author":"E Higashihara","year":"2024","unstructured":"Higashihara E, Harada T, Fukuhara H. Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease. Expert Opin Pharmacother. 2024;25:819\u201332.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02589-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:04:04Z","timestamp":1746288244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02589-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EH has no conflict of interest to declare. MM is an employee of Otsuka Pharmaceutical Co., Ltd., Japan. HJ is an employee of Otsuka Pharmaceutical Development & Commercialization, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}